Advancing Insulin Therapy in Type 2 Diabetes Previously Treated With Glargine Plus Oral Agents
Prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy
- Julio Rosenstock, MD1,
- Andrew J. Ahmann, MD2,
- Gildred Colon, MD3,
- Jamie Scism-Bacon, PHD4,
- Honghua Jiang, PHD4 and
- Sherry Martin, MD4
- 1Dallas Diabetes and Endocrine Center, Dallas, Texas
- 2Oregon Health and Science University, Portland, Oregon
- 3San Juan Health Centre, San Juan, Puerto Rico
- 4U.S. Medical Division, Eli Lilly and Company, Indianapolis, Indiana
- Address correspondence and reprint requests to Julio Rosenstock, MD, Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX 75230. E-mail: juliorosenstock{at}dallasdiabetes.com
Abstract
OBJECTIVE—The purpose of this study was to compare two analog insulin therapies (prandial premixed therapy [PPT] versus basal/bolus therapy [BBT]) in type 2 diabetic patients previously treated with insulin glargine (≥30 units/day) plus oral agents, with the aim of demonstrating noninferiority of PPT to BBT.
RESEARCH DESIGN AND METHODS—Patients were randomly assigned to PPT (lispro mix 50/50: 50% insulin lispro protamine suspension and 50% lispro; n = 187) t.i.d. with meals or BBT (glargine at bedtime plus mealtime lispro; n = 187) in a 24-week, multicenter, open-label, noninferiority trial. Investigators could replace lispro mix 50/50 with lispro mix 75/25 at the evening meal if the fasting plasma glucose target was unachievable.
RESULTS—Baseline A1C was similar (PPT 8.8%; BBT 8.9%; P = 0.598). At week 24, A1C was lower with BBT (6.78 vs. 6.95%, P = 0.021). A1C was reduced significantly from baseline for both therapies (P < 0.0001). The difference in A1C change from baseline to the end point (BBT minus PPT) was −0.22% (90% CI −0.38 to −0.07). Noninferiority of PPT to BBT was not demonstrated based on the prespecified noninferiority margin of 0.3%. The percentages of patients achieving target A1C <7.0% (PPT versus BBT, respectively) were 54 vs. 69% (P = 0.009) and for target ≤6.5% were 35 vs. 50% (P = 0.01) but did not differ for target ≤6.0% or <7.5%. Rates of hypoglycemia were similar for both groups.
CONCLUSIONS—Although noninferiority of PPT to BBT was not demonstrated, findings for A1C reduction, percentage of patients achieving A1C targets, hypoglycemia, and number of required injections should be considered in the individual decision-making process of advancing insulin replacement to PPT versus BBT in type 2 diabetes.
- BBT, basal/bolus therapy
- FPG, fasting plasma glucose
- OHA, oral antihyperglycemic agent
- PPT, prandial premixed therapy
- SAE, severe adverse event
- SMPG, self-monitored plasma glucose
- TDI, total daily insulin
Footnotes
-
Published ahead of print at http://care.diabetesjournals.org on 12 October 2007. DOI: 10.2337/dc07-1122. Clinical trial reg. no. NCT00110370, clinicaltrials.gov.
J.R. has received grant support for clinical studies and also consulting fees for serving on advisory boards from Eli Lilly, sanofi-aventis, and Novo Nordisk. A.J.A. has received honoraria for serving on advisory boards of and as a speaker for Eli Lilly and Company and sanofi-aventis. G.C. has received consulting fees for being a member of the Scientific Advisory Board on Erectile Dysfunction and the Diabetes Advisory Board from Eli Lilly and Company.
Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/dc07-1122.
Funding for this study was provided by Eli Lilly and Company. Authors affiliated with Eli Lilly were involved in the study conceptualization, design, and interpretation of results as well as authoring of this article.
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.
-
- Accepted October 4, 2007.
- Received June 13, 2007.
- DIABETES CARE
